Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia | Zendy

Per-Ola Attman | Zendy; Pia Ottosson | Zendy; Ola Samuelsson | Zendy; Ulf G. Eriksson | Zendy; Maria Eriksson-Lepkowska | Zendy; Gunnar Fager | Zendy

Open Access

Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia

Author(s) -

Per-Ola Attman,

Pia Ottosson,

Ola Samuelsson,

Ulf G. Eriksson,

Maria Eriksson-Lepkowska,

Gunnar Fager

Publication year - 2005

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfh915

Subject(s) - medicine , dialysis , hemodialysis , direct thrombin inhibitor , bolus (digestion) , surgery , warfarin , atrial fibrillation , dabigatran

This study assessed the feasibility of replacing intravenous (i.v.) dalteparin with the direct thrombin inhibitor (DTI) melagatran administered via dialysis fluid in patients undergoing haemodialysis, and also examined the pharmacokinetics of melagatran with and without dialysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog